RheoDx is looking for one million euros to accelerate blood diagnostics

RheoDx, on the hunt for a million euros to accelerate in blood diagnostics RheoDx, facing its year of consolidation. The Spanish startup has received €669,000 from the Center for the Development of Industrial Technology (Cdti) through the Cervera Program. The company is developing a small, portable diagnostic device that improves efficiency in the monitoring of patients with hematological diseases. 

The company will use the funding to accelerate in blood diagnostics and will seek to accompany it with a $360,000 (€300,000) financing round. In total, the company is looking to raise $1.2 million (€1 million) by 2021 to consolidate the project, said Alfred Serra, CEO of RheoDx. 

The device developed by the start-up allows immediate and inexpensive detection of blood cell abnormalities by means of a single drop of blood where the patient is. The company has recently initiated clinical studies.  

Read more about RheoDx’s new device and find the most important business news of the day with our companion app. The Born2Invest mobile app keeps its readers up to date with the latest breakthroughs in the biotech sector and the latest market updates.

RheoDx expects to start marketing its device in late 2022 or early 2023 

RheoDx is a technology-based company born from the Center for Mathematical Research (CRM), the University of Barcelona and Collider, an initiative of the Mobile World Capital Foundation. The project got the patent on its development in 2016, but the company was not founded until 2018. 

The startup has begun clinical studies at the Josep Carreras Leukemia Research Institute, the Hospital de la Santa Creu i Sant Pau and the Catalan Institute of Oncology with the aim of obtaining CE and U.S. Food and Drug Administration (FDA) marking. Serra assures that “in the future we will be able to determine any type of disease through blood diagnosis.” 

Through Cdti funding, the company expects to have the prototype device ready in June. The company estimates that 20% of transfusions performed each year are unnecessary, and its device could reduce that cost. The device is aimed at a market of 80 million patients in Europe, including anemias, liquid cancers, coagulation disorders and infections such as malaria.  

The company has raised about half a million euros since its founding in 2018 

RheoDx estimates starting commercialization of the medically focused device in late 2022 or early 2023. However, the startup plans to bring it to market for other purposes such as the food industry and start billing. 

The medtech company was founded by Aurora Herández-Machado, a professor of physics. Since its foundation, the startup has raised close to half a million euros. The company closed a funding round of $419,000 (€350,000) on the crowdfunding platform Capital Cell, has received financial support from Enisa and $90,000 (€75,000 from) Acció, in addition to contributions from the founding partners. RheoDx, based in Barcelona, currently has four employees.

__

(Featured image by martaposemuckel via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.